Torill Ueland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Torill Ueland has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
- Ole Andreas Andreassen
Institute of Clinical Medicine, University of Oslo, Oslo, Norway
13 shared publications - Ingrid Melle
Oslo University Hospital & Institute of Clinical Medicine, University of Oslo
7 shared publications - Nils Eiel Steen
Centre for Precision Psychiatry, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
7 shared publications - Anja Vaskinn
Centre for Research and Education in Forensic Psychiatry, Oslo University Hospital, Oslo, Norway
6 shared publications - Linn Sofie Sæther
Oslo University Hospital
6 shared publications - Beathe Haatveit
NORMENT, Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Oslo, Norway
5 shared publications
Latest Publications
- Open Access
- 19 March 2026
- Published by Elsevier in Schizophrenia Research: Cognition
- Vol. 45, 100429
Reply to Stip and colleagues
- 19 March 2026
- Published by Elsevier in Schizophrenia Research: Cognition
- Vol. 45, 100429
Open AccessReply to Stip and colleagues
- 10 January 2026
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 117, 104852
PrecInNor: An Indo-Norway collaborative programme for precision psychiatry training
- 10 January 2026
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 117, 104852
PrecInNor: An Indo-Norway collaborative programme for precision psychiatry training
- Open Access
- 12 September 2025
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 68 (1) , 1-28
Minor immunomodulatory effects of psychotropics suggested in severe mental disorders: Associations of antipsychotics with beta defensin 2, antidepressants with C-reactive protein, and mood stabilizers with soluble interleukin 2 receptor
Background: Immunomodulatory effects of psychotropic agents used to treat severe mental disorders (SMDs) have been suggested. We investigated associations between immune marker levels and antipsychotic- (AP), antidepressant- (AD), and mood stabilizing agents (MS) use in SMDs. Methods: We included 1215 participants with SMDs (777 with schizophrenia spectrum disorders and 438 with bipolar disorders). Circulating levels of 45 immune markers were determined by enzyme-immunoassay or immunoturbidimetry and analyzed for associations with use, doses, and serum concentrations of AP, AD, and MS. Extensive adjustments for potential confounders were performed. Immune marker levels of 1008 healthy controls served as a reference. Results: AP use was significantly associated with higher plasma levels of beta defensin 2 (BD-2) (β = 0.094, p = 0.8E-4), AD use with higher serum levels of CRP (β = 0.072, p = 0.8E-3), and MS use with higher plasma levels of soluble interleukin 2 receptor (sIL-2R) (β = 0.063, p = 0.9E-4). These findings were paralleled by positive associations with psychotropic agent dose and serum concentrations: AP dose was associated with BD-2 levels (β = 0.045, p = 2.3E-4), AD dose with CRP levels (β = 0.039, p = 0.001), MS dose with sIL-2R levels (β = 0.048, p = 0.001), and serum concentration of AD was nominally positively associated with CRP (β = 0.072, p = 0.002). Conclusions: The findings suggest that AP and MS use affect pathways involved in immune homeostasis and inflammatory regulation in individuals with SMDs, while AD use augments low-grade systemic inflammation reflected by CRP.
- 12 September 2025
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 68 (1) , 1-28
Open AccessMinor immunomodulatory effects of psychotropics suggested in severe mental disorders: Associations of antipsychotics with beta defensin 2, antidepressants with C-reactive protein, and mood stabilizers with soluble interleukin 2 receptor
Background: Immunomodulatory effects of psychotropic agents used to treat severe mental disorders (SMDs) have been suggested. We investigated associations between immune marker levels and antipsychotic- (AP), antidepressant- (AD), and mood stabilizing agents (MS) use in SMDs. Methods: We included 1215 participants with SMDs (777 with schizophrenia spectrum disorders and 438 with bipolar disorders). Circulating levels of 45 immune markers were determined by enzyme-immunoassay or immunoturbidimetry and analyzed for associations with use, doses, and serum concentrations of AP, AD, and MS. Extensive adjustments for potential confounders were performed. Immune marker levels of 1008 healthy controls served as a reference. Results: AP use was significantly associated with higher plasma levels of beta defensin 2 (BD-2) (β = 0.094, p = 0.8E-4), AD use with higher serum levels of CRP (β = 0.072, p = 0.8E-3), and MS use with higher plasma levels of soluble interleukin 2 receptor (sIL-2R) (β = 0.063, p = 0.9E-4). These findings were paralleled by positive associations with psychotropic agent dose and serum concentrations: AP dose was associated with BD-2 levels (β = 0.045, p = 2.3E-4), AD dose with CRP levels (β = 0.039, p = 0.001), MS dose with sIL-2R levels (β = 0.048, p = 0.001), and serum concentration of AD was nominally positively associated with CRP (β = 0.072, p = 0.002). Conclusions: The findings suggest that AP and MS use affect pathways involved in immune homeostasis and inflammatory regulation in individuals with SMDs, while AD use augments low-grade systemic inflammation reflected by CRP.
- Open Access
The Art of Not Knowing: Accommodating Structured Missingness in Biomedical Research
Missing data remain a ubiquitous and critical challenge in large-scale clinical studies. Despite advances in imputation, most existing methods fail to address structured missingness, where data are missing according a deterministic pattern and which arise due to systematic patterns introduced by experimental design, site protocols, or cohort differences. These patterns violate key assumptions of most imputation algorithms, yet their impact is rarely evaluated. We demonstrate that structured missingness is a fundamental challenge to drawing valid inferences from standard imputation techniques. First, we present a comprehensive framework for understanding and accommodating the effects of structured missingness. Next, we show through simulations and real-world psychometric data with structured missingness, that widely used algorithms optimised for numerical precision (e.g., Extra Trees, AutoComplete) underperform due to site effects, while donor-based methods (e.g., MICE, hierarchical MICE) better preserve multivariate structure. We propose a novel hierarchical approach that provides optimal performance in simulated and experimental data. Finally, we show that commonly used accuracy metrics, such as mean squared error can obscure these failures, and are therefore inadequate for the evaluation of structured missingness. In contrast, other divergence-based metrics offer a more sensitive and interpretable alternative. We apply this approach to harmonising psychometric data across cohorts, which provides excellent item-level alignment across different instruments. Our study highlights the need for a paradigm shift in handling missing data within biomedical research, moving beyond conventional imputation frameworks to develop tools that can account for structured missingness. This shift is essential for ensuring reliable inference in multi-site clinical studies, precision medicine, and large-scale population analyses.
Open AccessThe Art of Not Knowing: Accommodating Structured Missingness in Biomedical Research
Missing data remain a ubiquitous and critical challenge in large-scale clinical studies. Despite advances in imputation, most existing methods fail to address structured missingness, where data are missing according a deterministic pattern and which arise due to systematic patterns introduced by experimental design, site protocols, or cohort differences. These patterns violate key assumptions of most imputation algorithms, yet their impact is rarely evaluated. We demonstrate that structured missingness is a fundamental challenge to drawing valid inferences from standard imputation techniques. First, we present a comprehensive framework for understanding and accommodating the effects of structured missingness. Next, we show through simulations and real-world psychometric data with structured missingness, that widely used algorithms optimised for numerical precision (e.g., Extra Trees, AutoComplete) underperform due to site effects, while donor-based methods (e.g., MICE, hierarchical MICE) better preserve multivariate structure. We propose a novel hierarchical approach that provides optimal performance in simulated and experimental data. Finally, we show that commonly used accuracy metrics, such as mean squared error can obscure these failures, and are therefore inadequate for the evaluation of structured missingness. In contrast, other divergence-based metrics offer a more sensitive and interpretable alternative. We apply this approach to harmonising psychometric data across cohorts, which provides excellent item-level alignment across different instruments. Our study highlights the need for a paradigm shift in handling missing data within biomedical research, moving beyond conventional imputation frameworks to develop tools that can account for structured missingness. This shift is essential for ensuring reliable inference in multi-site clinical studies, precision medicine, and large-scale population analyses.
- Open Access
- 28 January 2025
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin Open
- Vol. 6 (1)
Learning Latent Profiles via Cognitive Growth Charting in Psychosis: Design and Rationale for the PRECOGNITION Project
Background and Hypothesis: Cognitive impairments are a core feature of psychosis that are often evident before illness onset and have substantial impact on both clinical and real-world functional outcomes. Therefore, these are an excellent target for stratification and early detection in order to facilitate early intervention. While many studies have aimed to characterize the effects of cognition at the group level and others have aimed to detect individual differences by referencing subjects against existing norms, these studies have limited generalizability across clinical populations, demographic backgrounds, and instruments and do not fully account for the interindividual heterogeneity inherent in psychosis. Study Design: Here, we outline the rationale, design, and analysis plan for the PRECOGNITION project, which aims to address these challenges. Study Results: This project is a collaboration between partners in 5 European countries. The project will not generate any primary data, but by leveraging existing datasets and combining these with novel analytic methods, it will produce multiple contributions including: (i) translating normative modeling approaches pioneered in brain imaging to psychosis data, to yield “cognitive growth charts” for longitudinal tracking and individual prediction; (ii) developing machine learning models for harmonizing and stratifying cohorts on the basis of these models; and (iii) providing integrated next-generation norms, having broad sociodemographic coverage including different languages and distinct norms for individuals with psychosis and unaffected individuals. Conclusions: This study will enable precision stratification of psychosis cohorts and furnish predictions for a broad range of functional outcome measures. It will be guided throughout by lived experience experts.
- 28 January 2025
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin Open
- Vol. 6 (1)
Open AccessLearning Latent Profiles via Cognitive Growth Charting in Psychosis: Design and Rationale for the PRECOGNITION Project
Background and Hypothesis: Cognitive impairments are a core feature of psychosis that are often evident before illness onset and have substantial impact on both clinical and real-world functional outcomes. Therefore, these are an excellent target for stratification and early detection in order to facilitate early intervention. While many studies have aimed to characterize the effects of cognition at the group level and others have aimed to detect individual differences by referencing subjects against existing norms, these studies have limited generalizability across clinical populations, demographic backgrounds, and instruments and do not fully account for the interindividual heterogeneity inherent in psychosis. Study Design: Here, we outline the rationale, design, and analysis plan for the PRECOGNITION project, which aims to address these challenges. Study Results: This project is a collaboration between partners in 5 European countries. The project will not generate any primary data, but by leveraging existing datasets and combining these with novel analytic methods, it will produce multiple contributions including: (i) translating normative modeling approaches pioneered in brain imaging to psychosis data, to yield “cognitive growth charts” for longitudinal tracking and individual prediction; (ii) developing machine learning models for harmonizing and stratifying cohorts on the basis of these models; and (iii) providing integrated next-generation norms, having broad sociodemographic coverage including different languages and distinct norms for individuals with psychosis and unaffected individuals. Conclusions: This study will enable precision stratification of psychosis cohorts and furnish predictions for a broad range of functional outcome measures. It will be guided throughout by lived experience experts.
- Open Access
- 23 January 2025
- Published by Cambridge University Press (CUP) in Acta Neuropsychiatrica
- Vol. 37, e4
Limited evidence of association between dysregulated immune marker levels and telomere length in severe mental disorders
Objective: Accelerated ageing indexed by telomere attrition is suggested in schizophrenia spectrum- (SCZ) and bipolar disorders (BD). While inflammation may promote telomere shortening, few studies have investigated the association between telomere length (TL) and markers of immune activation and inflammation in severe mental disorders. Methods: Leucocyte TL defined as telomere template/amount of single-copy gene template (T/S ratio), was determined in participants with SCZ (N = 301) or BD (N = 211) and a healthy control group (HC, N = 378). TL was analysed with linear regressions for associations with levels of 12 immune markers linked to SCZ or BD. Adjustments were made for a broad range of potential confounding variables. TL was measured by quantitative polymerase chain reaction (qPCR) and the immune markers were measured by enzyme immunoassays. Results: A positive association between levels of soluble tumour necrosis factor receptor 1A (sTNF-R1) and TL in SCZ (β = 0.191, p = 0.012) was observed. Plasma levels of the other immune markers were not significantly associated with TL in the BD, SCZ or HC groups. Conclusion: There was limited evidence of association between immune markers and TL in SCZ and BD. The results provide little support for involvement of immune dysregulation, as reflected by current systemic markers, in telomere attrition-related accelerated ageing in severe mental disorders.
- 23 January 2025
- Published by Cambridge University Press (CUP) in Acta Neuropsychiatrica
- Vol. 37, e4
Open AccessLimited evidence of association between dysregulated immune marker levels and telomere length in severe mental disorders
Objective: Accelerated ageing indexed by telomere attrition is suggested in schizophrenia spectrum- (SCZ) and bipolar disorders (BD). While inflammation may promote telomere shortening, few studies have investigated the association between telomere length (TL) and markers of immune activation and inflammation in severe mental disorders. Methods: Leucocyte TL defined as telomere template/amount of single-copy gene template (T/S ratio), was determined in participants with SCZ (N = 301) or BD (N = 211) and a healthy control group (HC, N = 378). TL was analysed with linear regressions for associations with levels of 12 immune markers linked to SCZ or BD. Adjustments were made for a broad range of potential confounding variables. TL was measured by quantitative polymerase chain reaction (qPCR) and the immune markers were measured by enzyme immunoassays. Results: A positive association between levels of soluble tumour necrosis factor receptor 1A (sTNF-R1) and TL in SCZ (β = 0.191, p = 0.012) was observed. Plasma levels of the other immune markers were not significantly associated with TL in the BD, SCZ or HC groups. Conclusion: There was limited evidence of association between immune markers and TL in SCZ and BD. The results provide little support for involvement of immune dysregulation, as reflected by current systemic markers, in telomere attrition-related accelerated ageing in severe mental disorders.
- Open Access
Predicting Mental and Neurological Illnesses Based on Cerebellar Normative Features
Mental and neurological conditions have been linked to structural brain variations. However, aside from dementia, the value of brain structural characteristics derived from brain scans for prediction is relatively low. One reason for this limitation is the clinical and biological heterogeneity inherent to such conditions. Recent studies have implicated aberrations in the cerebellum – a relatively understudied brain region – in these clinical conditions. Here, we used machine learning to test the value of individual deviations from normative cerebellar development across the lifespan (based on trained data from >27k participants) for prediction of autism spectrum disorder (ASD) (n=317), bipolar disorder (BD) (n=238), schizophrenia (SZ) (n=195), mild cognitive impairment (MCI) (n=122), and Alzheimer’s disease (AD) (n=116). We applied several atlases and derived median, variance, and percentages of extreme deviations within each region of interest. Our results show that lobular and voxel-wise cerebellar data can be used to discriminate healthy controls from ASD and SZ with moderate accuracy (the area under the receiver operating characteristic curves ranged from 0.56 to 0.64), The strongest contributions to these predictive models were from posterior regions of the cerebellum, which are more strongly linked to higher cognitive functions than to motor control.
Open AccessPredicting Mental and Neurological Illnesses Based on Cerebellar Normative Features
Mental and neurological conditions have been linked to structural brain variations. However, aside from dementia, the value of brain structural characteristics derived from brain scans for prediction is relatively low. One reason for this limitation is the clinical and biological heterogeneity inherent to such conditions. Recent studies have implicated aberrations in the cerebellum – a relatively understudied brain region – in these clinical conditions. Here, we used machine learning to test the value of individual deviations from normative cerebellar development across the lifespan (based on trained data from >27k participants) for prediction of autism spectrum disorder (ASD) (n=317), bipolar disorder (BD) (n=238), schizophrenia (SZ) (n=195), mild cognitive impairment (MCI) (n=122), and Alzheimer’s disease (AD) (n=116). We applied several atlases and derived median, variance, and percentages of extreme deviations within each region of interest. Our results show that lobular and voxel-wise cerebellar data can be used to discriminate healthy controls from ASD and SZ with moderate accuracy (the area under the receiver operating characteristic curves ranged from 0.56 to 0.64), The strongest contributions to these predictive models were from posterior regions of the cerebellum, which are more strongly linked to higher cognitive functions than to motor control.
- Open Access
- 27 September 2024
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 122, 105-112
Unraveling the shared genetics of common epilepsies and general cognitive ability
- 27 September 2024
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 122, 105-112
Open AccessUnraveling the shared genetics of common epilepsies and general cognitive ability
- Open Access
- 1 September 2024
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 54 (12) , 3519-3529
Longitudinal course of inflammatory-cognitive subgroups across first treatment severe mental illness and healthy controls
Background: While inflammation is associated with cognitive impairment in severe mental illnesses (SMI), there is substantial heterogeneity and evidence of transdiagnostic subgroups across schizophrenia (SZ) and bipolar (BD) spectrum disorders. There is however, limited knowledge about the longitudinal course of this relationship.Methods: Systemic inflammation (C-Reactive Protein, CRP) and cognition (nine cognitive domains) was measured from baseline to 1 year follow-up in first treatment SZ and BD (n = 221), and healthy controls (HC, n = 220). Linear mixed models were used to evaluate longitudinal changes separately in CRP and cognitive domains specific to diagnostic status (SZ, BD, HC). Hierarchical clustering was applied on the entire sample to investigate the longitudinal course of transdiagnostic inflammatory-cognitive subgroups.Results: There were no case-control differences or change in CRP from baseline to follow-up. We confirm previous observations of case-control differences in cognition at both time-points and domain specific stability/improvement over time regardless of diagnostic status. We identified transdiagnostic inflammatory-cognitive subgroups at baseline with differing demographics and clinical severity. Despite improvement in cognition, symptoms and functioning, the higher inflammation – lower cognition subgroup (75% SZ; 48% BD; 38% HC) had sustained inflammation and lower cognition, more symptoms, and lower functioning (SMI only) at follow-up. This was in comparison to a lower inflammation – higher cognition subgroup (25% SZ, 52% BD, 62% HC), where SMI participants showed cognitive functioning at HC level with a positive clinical course.Conclusions: Our findings support heterogenous and transdiagnostic inflammatory-cognitive subgroups that are stable over time, and may benefit from targeted interventions.
- 1 September 2024
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 54 (12) , 3519-3529
Open AccessLongitudinal course of inflammatory-cognitive subgroups across first treatment severe mental illness and healthy controls
Background: While inflammation is associated with cognitive impairment in severe mental illnesses (SMI), there is substantial heterogeneity and evidence of transdiagnostic subgroups across schizophrenia (SZ) and bipolar (BD) spectrum disorders. There is however, limited knowledge about the longitudinal course of this relationship.Methods: Systemic inflammation (C-Reactive Protein, CRP) and cognition (nine cognitive domains) was measured from baseline to 1 year follow-up in first treatment SZ and BD (n = 221), and healthy controls (HC, n = 220). Linear mixed models were used to evaluate longitudinal changes separately in CRP and cognitive domains specific to diagnostic status (SZ, BD, HC). Hierarchical clustering was applied on the entire sample to investigate the longitudinal course of transdiagnostic inflammatory-cognitive subgroups.Results: There were no case-control differences or change in CRP from baseline to follow-up. We confirm previous observations of case-control differences in cognition at both time-points and domain specific stability/improvement over time regardless of diagnostic status. We identified transdiagnostic inflammatory-cognitive subgroups at baseline with differing demographics and clinical severity. Despite improvement in cognition, symptoms and functioning, the higher inflammation – lower cognition subgroup (75% SZ; 48% BD; 38% HC) had sustained inflammation and lower cognition, more symptoms, and lower functioning (SMI only) at follow-up. This was in comparison to a lower inflammation – higher cognition subgroup (25% SZ, 52% BD, 62% HC), where SMI participants showed cognitive functioning at HC level with a positive clinical course.Conclusions: Our findings support heterogenous and transdiagnostic inflammatory-cognitive subgroups that are stable over time, and may benefit from targeted interventions.